AR073585A1 - A PROTEIN RICH IN CYSTEINE DERIVED FROM SERUM IN PATIENTS WHO RECEIVE CHEMOTHERAPY OR RADIOTHERAPY TO IMPROVE THE SURVIVAL OF SUCH PATIENTS. USE. METHOD - Google Patents

A PROTEIN RICH IN CYSTEINE DERIVED FROM SERUM IN PATIENTS WHO RECEIVE CHEMOTHERAPY OR RADIOTHERAPY TO IMPROVE THE SURVIVAL OF SUCH PATIENTS. USE. METHOD

Info

Publication number
AR073585A1
AR073585A1 ARP090103512A ARP090103512A AR073585A1 AR 073585 A1 AR073585 A1 AR 073585A1 AR P090103512 A ARP090103512 A AR P090103512A AR P090103512 A ARP090103512 A AR P090103512A AR 073585 A1 AR073585 A1 AR 073585A1
Authority
AR
Argentina
Prior art keywords
patients
survival
cysteine
serum
improve
Prior art date
Application number
ARP090103512A
Other languages
Spanish (es)
Inventor
Wulf Droge
Gustavo Bounous
John H Molson
Original Assignee
2458781 Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002639562A external-priority patent/CA2639562A1/en
Priority claimed from US12/210,030 external-priority patent/US20100069288A1/en
Application filed by 2458781 Canada Inc filed Critical 2458781 Canada Inc
Publication of AR073585A1 publication Critical patent/AR073585A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Abstract

Reivindicacion 1: Una proteína rica en cisteína derivada de suero desnaturalizado caracterizada porque es para usar en quimioterapia, en terapia con radiacion o en ambas, para incrementar la supervivencia del paciente. Reivindicacion 4: La proteína rica en cisteína de cualquiera de las reivindicaciones 1 a 3, caracterizada porque se administra diariamente en una cantidad de aproximadamente entre 5 y 30 g. Reivindicacion 8: Un método para tratar un paciente con cáncer para mejorar su supervivencia en la quimioterapia, en la terapia con radiacion o en ambas, caracterizado porque comprende administrarle una proteína rica en cisteína derivada de suero desnaturalizado. Reivindicacion 10: El método de la reivindicacion 8 o 9, caracterizado porque el paciente recibe un tratamiento para el cáncer de pulmon.Claim 1: A cysteine-rich protein derived from denatured serum characterized in that it is for use in chemotherapy, radiation therapy or both, to increase patient survival. Claim 4: The cysteine-rich protein of any one of claims 1 to 3, characterized in that it is administered daily in an amount of approximately 5 to 30 g. Claim 8: A method for treating a cancer patient to improve their survival in chemotherapy, radiation therapy or both, characterized in that it comprises administering a protein rich in cysteine derived from denatured serum. Claim 10: The method of claim 8 or 9, characterized in that the patient receives a treatment for lung cancer.

ARP090103512A 2008-09-12 2009-09-11 A PROTEIN RICH IN CYSTEINE DERIVED FROM SERUM IN PATIENTS WHO RECEIVE CHEMOTHERAPY OR RADIOTHERAPY TO IMPROVE THE SURVIVAL OF SUCH PATIENTS. USE. METHOD AR073585A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002639562A CA2639562A1 (en) 2008-09-12 2008-09-12 Use of cysteine-rich whey derived protein in patients receiving chemotherapy or radiotherapy to improve patient survival
US12/210,030 US20100069288A1 (en) 2008-09-12 2008-09-12 Use of cysteine-rich whey derived protein in patients receiving chemotherapy or radiotherapy to improve patient survival

Publications (1)

Publication Number Publication Date
AR073585A1 true AR073585A1 (en) 2010-11-17

Family

ID=42004761

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103512A AR073585A1 (en) 2008-09-12 2009-09-11 A PROTEIN RICH IN CYSTEINE DERIVED FROM SERUM IN PATIENTS WHO RECEIVE CHEMOTHERAPY OR RADIOTHERAPY TO IMPROVE THE SURVIVAL OF SUCH PATIENTS. USE. METHOD

Country Status (3)

Country Link
AR (1) AR073585A1 (en)
TW (1) TWI515005B (en)
WO (1) WO2010028503A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8163796B1 (en) 2009-07-28 2012-04-24 BioChemical Solutions, LLC Treatment of cancer by oxidation-reduction potentiation of cancerostatic dicarbonyls
EP2444083A1 (en) 2010-10-21 2012-04-25 Nestec S.A. Cysteine and food intake
IT201800005714A1 (en) * 2018-05-25 2019-11-25 CONCENTRATE OF WHEY PROTEIN IN ASSOCIATION WITH ANTI-TUMOR TREATMENT

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338682C (en) * 1988-12-23 1996-10-29 Gustavo Bounous Biologically active undenatured whey protein concentrate as food supplement

Also Published As

Publication number Publication date
TWI515005B (en) 2016-01-01
TW201014599A (en) 2010-04-16
WO2010028503A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
CY1120022T1 (en) Pediatric Acute Acute Lymphoblastic Leukemia Treatment
AR060306A1 (en) ANTIBODY COMBINATION THERAPY AGAINST CTLA4
ME01133B (en) Combination therapy with peptide epoxyketones
EA201000914A1 (en) NEW THERAPEUTIC APPROACHES IN THE TREATMENT OF SMT AND RELATED DISORDERS
BR112015019064A8 (en) use of a composition comprising nanoparticles comprising paclitaxel and an albumin for the treatment of melanoma and kit
EA200700493A1 (en) NEW APPLICATION OF PEPTIDE COMPOUNDS FOR THE TREATMENT OF PATIENTS WITH BONE CANCER, AND ALSO PAIN CAUSED BY CHEMOTHERAPY AND NUCLEOSID
MX2020009773A (en) Combination therapy.
EA200601777A1 (en) NEW APPLICATION OF PEPTIDE COMPOUNDS FOR THE TREATMENT OF PATIENTS WITH PATIENTS WITH DIABETIC DIABETIC NEUROPATHY
AR074203A1 (en) ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF BREAST CANCER. KIT USE.
GT200600115A (en) METHOD FOR IDENTIFYING THERAPEUTIC WHITES FOR THE TREATMENT OF VULVOGINAL ATROPHY
TW200630105A (en) Herbal composition PHY906 and its use in chemotherapy
AR092899A1 (en) USE OF MASITINIB FOR THE TREATMENT OF CANCER IN SUB-POPULATIONS OF IDENTIFIED PATIENTS USING PREDICTION FACTORS
PH12021551540A1 (en) Anti-il-36r antibodies for treatment of palmoplantar pustulosis
EA201300421A1 (en) COMBINED THERAPY FOR THE TREATMENT OF HCV INFECTION
ATE543492T1 (en) TREATMENT OF LUNG CANCER
AR086422A1 (en) METHOD FOR THE TREATMENT OF ADVANCED SOLID TUMORS, VOLASERTIB
CL2019000846A1 (en) Therapeutic protein.
EA200970345A1 (en) TREATMENT OF HYPERBILIRUBINEMIA OF NEWBORNS WITH THE USE OF LOW DOSING OF STANNSOPORFIN
AR073585A1 (en) A PROTEIN RICH IN CYSTEINE DERIVED FROM SERUM IN PATIENTS WHO RECEIVE CHEMOTHERAPY OR RADIOTHERAPY TO IMPROVE THE SURVIVAL OF SUCH PATIENTS. USE. METHOD
EA202091112A1 (en) SOCRYSTALS, PHARMACEUTICAL COMPOSITIONS BASED ON THEIR BASED AND METHODS OF TREATMENT FOR THEIR APPLICATION
EA202191165A1 (en) ELACESTRANT IN COMBINATION WITH ABEMACYCLIBUS IN WOMEN WITH BREAST CANCER
EA200600989A1 (en) APPLICATION OF GABOXADOL FOR THE TREATMENT OF CEREBELLS
NI201000185A (en) METHODS FOR USING CORTICOTROPIN RELEASING FACTOR FOR THE TREATMENT OF CANCER.
BR112018002433A2 (en) pharmaceutical composition for migraine treatment
EA201070295A1 (en) TREATMENT OF LUNG CANCER

Legal Events

Date Code Title Description
FB Suspension of granting procedure